Surena F. Matin - Concepedia

Author

Surena F. Matin

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Kathleen Kan, S F Matin, S Matin, S. F. Matin, S. Matin, S.F Matin, S.F. Matin, SURENA F. MATIN, SURENA F. Matin, SURENA FAZELI-MATIN

692

Publications

21.1K

Citations

H-Index

112

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Cleveland Clinic The University of Texas Southwestern Medical Center Penn State Milton S. Hershey Medical Center Moffitt Cancer Center

About

Surena F. Matin is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	40	94	6.4K
2	Health Sciences	7	7	172
3	Public Health	4	4	94
4	Engineering	1	1	30
5	Anatomy	1	1	11

Surena F. Matin

219

Publications

17.8K

Citations

H-Index

Page 1

	Year	Citations
Guideline for Management of the Clinical T1 Renal Mass Steven C. Campbell, Andrew C. Novick, Arie S. Belldegrun, The Journal of Urology	2009	1.8K
Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration Vitaly Margulis, Shahrokh F. Shariat, Surena F. Matin, Cancer	2009	1.1K
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial Naomi B. Haas, Judith Manola, Robert G. Uzzo, The Lancet UrologyGenitourinary CancerMedicinePharmacologyClinical Trials	2016	625
Comparative Analysis of Laparoscopic Versus Open Partial Nephrectomy for Renal Tumors in 200 Patients Inderbir S. Gill, Surena F. Matin, Mihir Desai, The Journal of Urology	2003	594
PROSPECTIVE RANDOMIZED COMPARISON OF TRANSPERITONEAL VERSUS RETROPERITONEAL LAPAROSCOPIC RADICAL NEPHRECTOMY Mihir Desai, BRENDA STRZEMPKOWSKI, Surena F. Matin, The Journal of Urology	2005	410
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma Lijun Zhou, Xian-De Liu, Mingli Sun, Oncogene UrologyMedicineMetronomic TherapyPharmacologyImmune Checkpoint Inhibitor	2015	386
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial Nizar M. Tannir, Eric Jonasch, Laurence Albigès, European Urology UrologyGenitourinary CancerMedicineCancer TreatmentOncology	2015	356
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma Jianjun Gao, Neema Navai, Omar Alhalabi, Nature Medicine Surgical OncologyUrologyGenitourinary CancerMedicineImmune Checkpoint Inhibitor	2020	300
A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer David J. McConkey, Woonyoung Choi, Yu Shen, European Urology UrologyGenitourinary CancerMedicinePathologyMolecular Classification	2015	275
Impact of Distal Ureter Management on Oncologic Outcomes Following Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma Évanguelos Xylinas, Michael Rink, K. Eugene, European Urology UrologySurgical OncologyDistal Ureter ManagementGenitourinary CancerMedicine	2012	251

Page 1